|
Birtamimab in patients with Mayo stage IV AL amyloidosis: Rationale for confirmatory affirm-AL phase 3 study. |
|
|
Honoraria - Abbvie; Akcea Therapeutics; Amgen; Apellis Pharmaceuticals; Celgene; Janssen Oncology; Juno/Celgene; Med Learning Group; Prothena; Research to Practice; Sanofi; Telix Pharmaceuticals |
Consulting or Advisory Role - Bristol-Myers Squibb/Sanofi; Prothena |
Travel, Accommodations, Expenses - Celgene; Novartis; Prothena |
|
|
Honoraria - Janssen; Pfizer |
Consulting or Advisory Role - Abbvie; Caelum Biosciences; Janssen Research & Development; Proclara; Protego Biopharma; Regeneron |
Research Funding - Caelum Biosciences (Inst); Celgene (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Oncopeptides (Inst); Prothena (Inst); Takeda (Inst) |
|
|
Honoraria - Janssen; Takeda |
Consulting or Advisory Role - Alexion Pharmaceuticals; Attralus; Prothena |
Speakers' Bureau - Janssen |
|
Travel, Accommodations, Expenses - Takeda |
|
|
Consulting or Advisory Role - Prothena |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Prothena |
|
|
|
Stock and Other Ownership Interests - Prothena |
|
|
|
Honoraria - Amgen; GlaxoSmithKline; Janssen; Pfizer; Takeda |
Consulting or Advisory Role - GlaxoSmithKline; Janssen |
Research Funding - Amgen; Janssen; Pfizer |
Travel, Accommodations, Expenses - Janssen |